SCHEMBL2611274

SCHEMBL2611274

Cc1cccc(OCc2nc3cc(C(=O)NO)ccc3c(=O)[nH]2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.51
RAB9A P51151 2/20 0.49
KMT2A Q03164 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 1/20 0.47
PSMD14 O00487 1/20 0.47
USP2 O75604 1/20 0.47
MAPT P10636 1/20 0.47
XBP1 P17861 1/20 0.47
HSD17B10 Q99714 1/20 0.47
ALPL P05186 1/20 0.45
ALPI P09923 1/20 0.45
ALPG P10696 1/20 0.45
CASP6 P55212 1/20 0.45
HDAC6 Q9UBN7 5/20 0.45
PDE5A O76074 1/20 0.45
KDM4E B2RXH2 2/20 0.44
RECQL P46063 1/20 0.44
HDAC8 Q9BY41 2/20 0.44
HDAC3 O15379 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2611393 0.89 RAB9A (0.49) HTTRAB9ASMN1; SMN2MAPTHDAC6
SCHEMBL2118827 0.87 RAB9A (0.47) RAB9AKMT2AMEN1PSMD14USP2
SCHEMBL2619265 0.85 KMT2A (0.47) RAB9AKMT2AMEN1PSMD14USP2
SCHEMBL4550064 0.85 KDM4E (0.46) HTTRAB9ASMN1; SMN2MAPTHSD17B10
SCHEMBL2611365 0.83 ROCK2 (0.44) HTTRAB9ASMN1; SMN2MAPTHDAC6
SCHEMBL2116314 0.83 RAB9A (0.49) HTTRAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL2619420 0.82 KDM4E (0.49) HTTRAB9ASMN1; SMN2MAPTHDAC6
SCHEMBL2611379 0.81 ROCK2 (0.53) RAB9AKMT2ASMN1; SMN2MEN1HDAC6
SCHEMBL2611268 0.80 HDAC6 (0.46) RAB9AKMT2AMEN1USP2MAPT
SCHEMBL4550080 0.79 KDM4E (0.40) HTTRAB9AKMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-11 US disclosed
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-11 US disclosed
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-11 US disclosed
US-8765773-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-8765773-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-8765773-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
WO-2012054332-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-26 WO disclosed
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-19 US disclosed
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 HTT 139/4885RAB9A 1243/4885KMT2A 35/4885
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 HTT 139/4885RAB9A 1243/4885KMT2A 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.